Here’s the accurate update:
💊 FDA approval status of Eli Lilly’s weight-loss pill
The drug you’re referring to is Foundayo (orforglipron).
✅ FDA approval
- The U.S. FDA approved Foundayo on April 1, 2026 for weight management in adults with obesity or weight-related health conditions
- It is a once-daily oral GLP-1 receptor agonist (a pill, not an injection)
- It can be taken without food or water restrictions, making it more convenient than earlier oral GLP-1 drugs
🧪 What makes it important
- It is one of the first major “next-generation” weight-loss pills competing with drugs like Wegovy
- In clinical trials, users lost significant body weight (around 12–27 lbs depending on dose and study group)
- It works by mimicking the GLP-1 hormone, which reduces appetite and slows digestion
💰 Availability
- In the U.S., it launched through LillyDirect and pharmacies shortly after approval
- Pricing starts around $149/month for self-pay users (higher doses cost more)
🧠 Important clarification
- It is FDA-approved (not experimental anymore)
- But like all GLP-1 drugs, it is meant for:
- Obesity, or
- Overweight with medical conditions (not general cosmetic use)
📉 Market context
- It entered a very competitive weight-loss drug market alongside injectable and oral GLP-1 medicines
- Early uptake is being closely watched against rivals like Novo Nordisk’s products
